Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882803 · ClinicalTrials.gov registry record · Phase 2
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT01882803 is a Phase 2 study that has completed, run by SecuraBio. The registered enrollment target is 129 participants.
The verdict
NCT01882803, a Phase 2 study, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).
Interventions
- DRUG Duvelisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2013-06-17 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01882803
The ClinicalTrials.gov registry entry for NCT01882803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Duvelisib is the first listed.
NCT01882803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01882803 about?
NCT01882803 is a clinical study titled "A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma". This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherap...
What is the current status of trial NCT01882803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2013-06-17. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT01882803?
The interventions under investigation include: Duvelisib (DRUG).
Who is sponsoring clinical trial NCT01882803?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.